Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Intellia Therapeutics

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Intellia Therapeutics excels in CRISPR trials, faces regulatory challenges

Intellia Therapeutics showcased promising clinical trial results, a strong financial position, and a commitment to advancing CRISPR-based therapies. While facing regulatory and strategic challenges, the company is well-positioned to capitalize on opportunities in gene editing technologies and global trials.

Intellia Therapeutics advances CRISPR therapies with strong financials and global interest

Intellia Therapeutics is making significant progress in advancing their CRISPR-based therapies, with strong financials and promising global interest in their programs. Challenges include dose selection and trial specifics, while opportunities exist in data presentation, regulatory acceleration, and therapeutic approaches.

Intellia Therapeutics reports strong Q2 performance and eyes global expansion

Intellia Therapeutics reported strong financials, progress in clinical programs, and positive patient outcomes. Challenges include pending decisions and regulatory factors. Opportunities exist in expanding market reach and monitoring industry developments.

Intellia Therapeutics progresses with NTLA-2001, faces competition challenges

Intellia Therapeutics demonstrated significant progress in drug development with FDA clearance for Phase 3 trial of NTLA-2001 and positive interim data, supported by a strong financial position.
The company's adaptability, collaborations, and focus on efficacy position it well for future growth, despite challenges in understanding treatment benefits and addressing competition.
Opportunities lie in robust trial designs, potential synergies with RNA silencers, sustained financial support, and enhancing treatment outcomes and patient experience.
Analysts' interest in trial details and future prospects underscores confidence in Intellia's advancements and potential impact in the biotech industry.

Intellia Therapeutics excels in 2023, eyes CRISPR breakthroughs in 2024

Intellia Therapeutics had a strong financial year with a focus on advancing CRISPR-based therapies.
Confidence in pivotal study designs and collaborations present growth opportunities for the company.
Challenges include revenue adjustments and regulatory uncertainties that need to be navigated.
Overall, Intellia's strategic focus on genome editing and disease targets positions it well for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Sangamo Therapeutics

Verve Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

AbbVie

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

Global X Genomics & Biotechnology ETF

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe.

3 Gene Editing Stocks With the Best Long-Term Potential

The consensus price target hints at an 185.4% upside potential for Intellia Therapeutics, Inc. (NTLA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?

CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE). The Innovation Passport is the point of entry into the U.K.'s Innovative Licensing and Access Pathway (ILAP), which is designed to accelerate time to market and facilitate patient access to innovative medicines.

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

AMC Entertainment

Global Business Travel Group I

Guardant Health Inc

Immunovant Inc

Maxar Technologies

Madrigal Pharmaceuticals

Mirati Therapeutics

Rumble Inc

Prometheus Biosciences

Mid-cap companies are fast-growing, young companies that are not as volatile as small-cap and not as stable as large-cap companies.

These Were the 5 Best and Worst Performing Mid-Cap Stocks in Dec 2022

CAMBRIDGE, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced its strategic priorities for the upcoming two years as the Company enters its next phase of pipeline execution and platform innovation.

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

AbCellera Biologics

AST SpaceMobile

JFrog

HashiCorp

MongoDB

UiPath

Planet Labs

Prime Medicine Inc

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

In-vivo CRISPR/Cas9 knock out gene editing treatments NTLA-2002 and NTLA-2001 have established proof of concept in treating patients with HAE and ATTR, respectively. Company has already gained the interest from big pharma for its CRISPR/Cas9 knock out gene editing technology platform from the likes of Regeneron and Novartis.

Intellia: In-Vivo Gene Editing Platform Continues To Deliver

Intellia is the first to show data in a tough field of medicine. The one-off offering has a sound attractiveness to it.

Intellia: Most Advanced In A Tough Field

Intellia Therapeutic's stock (NASDAQ: NTLA), a biotechnology company developing treatments using the CRISPR gene-editing system, has seen a fall of 31% in a month, while it's down 69% this year.

Will Intellia Therapeutics Stock Rebound After A 31% Fall In A Month?

Samsara

Lyft

Mid-cap land has long been regarded as the ‘sweet spot' for equity investors. Here are three mid-caps Wall Street sees as two-baggers over the next 12 months.

3 Mid-Caps That Could Double in 2023

Arista Networks

Broadcom

Daqo New Energy

Matson

Trane Technologies plc

The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023.

7 ‘Next Big Things' for Investors to Buy for 2023

Intellia Therapeutics (NASDAQ: NTLA ) stock is falling hard on Thursday after the company announced a public stock offering. The clinical-stage genome editing company is offering up 6,550,219 shares of NTLA stock for a price of $45.80 per share.

NTLA Stock Falls as Intellia Therapeutics Announces Public Offering

SparingVision's l ead asset SPVN06 clears IND application in the US for the treatment of r etinitis p igmentosa

SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosa

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, announced today the pricing of an underwritten public offering of 6,550,219 shares of its common stock at a public offering price of $45.80 per share. Intellia also granted the underwriter a 30-day option to purchase up to an additional 982,532 shares of its common stock. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $300 million, excluding any exercise of the underwriters' option to purchase additional shares. All of the shares in the offering are to be sold by Intellia.

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today announced that it has commenced an underwritten public offering of $250 million of shares of its common stock. Intellia also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of the shares of common stock offered in the public offering. All of the shares in the proposed offering are to be sold by Intellia.

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

Our theme on Gene Editing stocks remains down by 30% year-to-date, as rising interest rates have made investors prioritize value stocks and companies with strong cash flows over loss-making futuristic themes.

Clinical Progress And Depressed Prices Make This Biotech Theme Worth A Look

CAMBRIDGE, Mass., Nov. 12, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today announced updated data from an ongoing Phase 1/2 clinical study of NTLA-2002 for the treatment of hereditary angioedema (HAE). The interim analyses were shared today in a Distinguished Industry Abstract oral presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2022 Annual Scientific Meeting, being held November 10 – 14 in Louisville, Kentucky.

Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific Meeting

CAMBRIDGE, Mass., Nov. 05, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapeutics leveraging CRISPR-based technologies, today presented additional interim results from an ongoing Phase 1 clinical trial of NTLA-2001, an investigational, in vivo CRISPR/Cas9 genome editing therapy in development as a single-dose treatment for transthyretin (ATTR) amyloidosis in collaboration with Regeneron Pharmaceuticals. Results were presented in a Late-Breaking Science oral presentation at the American Heart Association (AHA) Scientific Sessions 2022, held November 5 – 7 in Chicago, Illinois.

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022

Intellia Therapeutics (NTLA) posts a wider-than-expected Q3 loss and sales also miss the mark. NTLA continues to advance its pipeline with developmental programs.

Intellia's (NTLA) Q3 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics, Inc. (NTLA) delivered earnings and revenue surprises of -13.74% and 2.48%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue Estimates

Intellia Therapeutics, Inc. (NASDAQ:NTLA ) Q3 2022 Results Earnings Conference Call November 3, 2022 8:00 AM ET Company Participants Ian Karp - Senior Vice President , Investor Relations and Corporate Communications John Leonard - President and Chief Executive Officer David Lebwohl - Executive Vice President and Chief Medical Officer Laura Sepp-Lorenzino - Executive Vice President and Chief Scientific Officer Glenn Goddard - Executive Vice President and Chief Financial Officer Conference Call Participants Mary Kate Davis - Bank of America Joseph Thome - Cowen and Company Brian Cheng - J.P. Morgan Richard Law - Credit Suisse Swapnil Malekar - Piper Sandler Dae Gon Ha - Stifel Terence Flynn - organ Stanley Maury Raycroft - Jefferies Jay Olson - Oppenheimer & Co. Luca Issi - RBC Capital Markets Joon Lee - Truist Securities Operator Good morning.

Intellia Therapeutics, Inc. (NTLA) Q3 2022 Results - Earnings Call Transcript

CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based technologies, today reported operational highlights and financial results for the third quarter ended September 30, 2022.

Intellia Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Recent Company Progress

- New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts - New data to include interim safety and kallikrein reduction data from 50 mg dose cohort, and additional safety, kallikrein reduction and attack rate data from 25 mg and 75 mg dose cohorts

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

News for Intellia Therapeutics Stock (NTLA)